Adaptive biotechnologies stock.

Some examples of biotechnology include human gene therapy, genetically modifying plants and changing the genes of bacteria. Biotechnology helps improve crops so they produce more, healthier produce. It also helps fight human diseases.May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ... Adaptive Biotechnologies stock soars 90% after ringing Nasdaq opening bell following $300M IPO. by James Thorne on June 27, 2019 at 8:08 am June 27, 2019 at 3:25 pm. Share 66 Tweet Share Reddit Email.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Delmaine Donson. Adaptive Biotechnologies (NASDAQ:ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May.The ...

Adaptive Biotechnologies Corp Stock Price: Bottom Line. As of September 7, 2023, Adaptive Biotechnologies Corp’s stock price is $6.30, which is down 4.11% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price.Nov 29, 2023 · What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings. Mar 9, 2023 · Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ...

Get Adaptive Biotechnologies Corp (ADPT.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... 12 Feb 2024 / 10:59 AM UTC Q4 2023 ...

Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT …Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight …Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Fiscal Q3 2023 ended 9/30/23. Reported on 11/9/23. Get the latest Adaptive Biotechnologies Corp (ADPT) real-time quote, historical performance, charts, and other financial information to help you...

Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...

Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...

Get Adaptive Biotechnologies Corp (ADPT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAug 2, 2023 · SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and …Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.Of course Adaptive Biotechnologies may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders ...Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic …About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human …

Adaptive Biotechnologies Corporation (ADPT) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » ADPT Adaptive …What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from the current ADPT share price of $4.37. SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.

Adaptive Biotechnologies shares are trading down 2.6% at $37.12 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete ...SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the strengths of Adaptive’s next-generation ...

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Delmaine Donson. Adaptive Biotechnologies (NASDAQ:ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May.The ...Aug 2, 2023 · Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ... SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ...

Jun 2, 2023 · As of June 02, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $7.46. Adaptive Biotechnologies Corp is up 5.82% from its previous closing price of $7.05. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $6.76 and $7.14. Currently, there are 143.51 million shares of Adaptive ...

Apr 11, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61.

Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. Adaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at MizuhoHow much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30 …Adaptive Biotechnologies stock rallies 14% on upgrade to Overweight at Piper Sandler SA News Wed, Dec. 21, 2022 Adaptive Biotechnologies GAAP EPS of -$0.32 beats by $0.06, revenue of $47.8M misses ...Ms. Rubinstein ADPT stock SEC Form 4 insiders trading. Julie has made over 40 trades of the Adaptive Biotechnologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 22,668 units of ADPT stock worth $194,265 on 6 March 2023.. The largest trade she's ever made was exercising 160,000 units of …Nov 17, 2023 · Adaptive Biotechnologies is forecast to grow earnings and revenue by 18.8% and 23.1% per annum respectively. EPS is expected to grow by 21.8% per annum. Return on equity is forecast to be -56.8% in 3 years. Adaptive Biotechnologies stock was originally listed at a price of $40.30 in Jun 27, 2019. If you had invested in Adaptive Biotechnologies stock at $40.30, your return over the last 4 years would have been -89.7%, for an annualized return of -43.35% (not including any dividends or dividend reinvestments).

Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQSEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or …Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of October 04, 2023, 4:00 PM, CST, Adaptive Biotechnologies Corp’s stock price was $4.81. Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30.Instagram:https://instagram. roku stocus half dollar valuevalue of half dollarsbest broker for indices ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million. wataxpdd stock forecast Adaptive Biotechnologies Corp Follow Share $4.62 After Hours: $4.62 (0.00%) 0.00 Closed: Nov 29, 4:18:17 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to AbbVie Inc $138.50 ABBV0.0072%... gsi technology BeiGene Ltd. Stock Performance and Financial Outlook: November 2023 Analysis. On November 7, 2023, BeiGene Ltd. (BGNE) experienced some fluctuations in its stock performance. The previous day’s close was recorded at $196.15, and the stock opened at $194.08. Throughout the day, the stock traded within a range of $194.08 to $197.57.Inside the Adaptive Biotech IPO: How two brothers built a big idea into a breakthrough company by James Thorne on June 2, 2019 at 10:52 am June 4, 2019 at 3:28 pm Share 18 Tweet Share Reddit Email